Fabry disease: Characterization of α-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele

Fabry disease, an X‐linked inborn error of glycosphingolipid catabolism, results from mutations in the gene encoding the lysosomal exoglycohydrolase, α‐galactosidase A (α‐Gal A; GLA). In two unrelated classically affected males, two α‐Gal A missense mutations were identified: R112C + D313Y (c.334C&g...

Full description

Saved in:
Bibliographic Details
Published inHuman mutation Vol. 22; no. 6; pp. 486 - 492
Main Authors Yasuda, Makiko, Shabbeer, Junaid, Benson, Stacy D., Maire, Irene, Burnett, Roger M., Desnick, Robert J.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.12.2003
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Fabry disease, an X‐linked inborn error of glycosphingolipid catabolism, results from mutations in the gene encoding the lysosomal exoglycohydrolase, α‐galactosidase A (α‐Gal A; GLA). In two unrelated classically affected males, two α‐Gal A missense mutations were identified: R112C + D313Y (c.334C>T + c.937G>T) and C172G + D313Y (c.514T>G + c.937G>T). The D313Y lesion was previously identified in classically affected males as the single mutation [Eng et al., 1993] or in cis with another missense mutation, D313Y + G411D (c.937G>T + c.1232G>A) [Guffon et al., 1998]. To determine whether the D313Y mutation was a deleterious mutation or a coding region sequence variant, the frequency of D313Y in normal X‐chromosomes, as well as its enzymatic activity and subcellular localization in COS‐7 cells was determined. D313Y occurred in 0.45% of 883 normal X‐chromosomes, while the R112C, C172G, and G411D missense mutations were not detected in over 500 normal X‐chromosomes. Expression of D313Y in COS‐7 cells resulted in& tilde;60% of wild‐type enzymatic activity and showed lysosomal localization, while R112C, C172G, G411D, and the double‐mutated constructs had markedly reduced or no detectable activity and were all retained in the endoplasmic reticulum. The expressed D313Y enzyme was stable at lysosomal pH (pH 4.6), while at neutral pH (pH 7.4), it had decreased activity. A molecular homology model of human α‐Gal A, based on the X‐ray crystal structure of chicken α‐galactosidase B (α‐Gal B; α‐N‐acetylgalactosaminidase) was generated [Garman et al., 2002], which provided evidence that D313Y did not markedly disrupt the α‐Gal A enzyme structure. Thus, D313Y is a rare exonic variant with about 60% of wild‐type activity in vitro and reduced activity at neutral pH, resulting in low plasma α‐Gal A activity. Hum Mutat 22:486–492, 2003. © 2003 Wiley‐Liss, Inc.
AbstractList Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from mutations in the gene encoding the lysosomal exoglycohydrolase, alpha-galactosidase A (alpha-Gal A; GLA). In two unrelated classically affected males, two alpha-Gal A missense mutations were identified: R112C + D313Y (c.334C>T + c.937G>T) and C172G + D313Y (c.514T>G + c.937G>T). The D313Y lesion was previously identified in classically affected males as the single mutation [Eng et al., 1993] or in cis with another missense mutation, D313Y + G411D (c.937G>T + c.1232G>A) [Guffon et al., 1998]. To determine whether the D313Y mutation was a deleterious mutation or a coding region sequence variant, the frequency of D313Y in normal X-chromosomes, as well as its enzymatic activity and subcellular localization in COS-7 cells was determined. D313Y occurred in 0.45% of 883 normal X-chromosomes, while the R112C, C172G, and G411D missense mutations were not detected in over 500 normal X-chromosomes. Expression of D313Y in COS-7 cells resulted in approximately 60% of wild-type enzymatic activity and showed lysosomal localization, while R112C, C172G, G411D, and the double-mutated constructs had markedly reduced or no detectable activity and were all retained in the endoplasmic reticulum. The expressed D313Y enzyme was stable at lysosomal pH (pH 4.6), while at neutral pH (pH 7.4), it had decreased activity. A molecular homology model of human alpha-Gal A, based on the X-ray crystal structure of chicken alpha-galactosidase B (alpha-Gal B; alpha-N-acetylgalactosaminidase) was generated [Garman et al., 2002], which provided evidence that D313Y did not markedly disrupt the alpha-Gal A enzyme structure. Thus, D313Y is a rare exonic variant with about 60% of wild-type activity in vitro and reduced activity at neutral pH, resulting in low plasma alpha-Gal A activity.
Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from mutations in the gene encoding the lysosomal exoglycohydrolase, alpha-galactosidase A (alpha-Gal A; GLA). In two unrelated classically affected males, two alpha-Gal A missense mutations were identified: R112C + D313Y (c.334C>T + c.937G>T) and C172G + D313Y (c.514T>G + c.937G>T). The D313Y lesion was previously identified in classically affected males as the single mutation [Eng et al., 1993] or in cis with another missense mutation, D313Y + G411D (c.937G>T + c.1232G>A) [Guffon et al., 1998]. To determine whether the D313Y mutation was a deleterious mutation or a coding region sequence variant, the frequency of D313Y in normal X-chromosomes, as well as its enzymatic activity and subcellular localization in COS-7 cells was determined. D313Y occurred in 0.45% of 883 normal X-chromosomes, while the R112C, C172G, and G411D missense mutations were not detected in over 500 normal X-chromosomes. Expression of D313Y in COS-7 cells resulted in approximately 60% of wild-type enzymatic activity and showed lysosomal localization, while R112C, C172G, G411D, and the double-mutated constructs had markedly reduced or no detectable activity and were all retained in the endoplasmic reticulum. The expressed D313Y enzyme was stable at lysosomal pH (pH 4.6), while at neutral pH (pH 7.4), it had decreased activity. A molecular homology model of human alpha-Gal A, based on the X-ray crystal structure of chicken alpha-galactosidase B (alpha-Gal B; alpha-N-acetylgalactosaminidase) was generated [Garman et al., 2002], which provided evidence that D313Y did not markedly disrupt the alpha-Gal A enzyme structure. Thus, D313Y is a rare exonic variant with about 60% of wild-type activity in vitro and reduced activity at neutral pH, resulting in low plasma alpha-Gal A activity.
Fabry disease, an X‐linked inborn error of glycosphingolipid catabolism, results from mutations in the gene encoding the lysosomal exoglycohydrolase, α‐galactosidase A (α‐Gal A; GLA). In two unrelated classically affected males, two α‐Gal A missense mutations were identified: R112C + D313Y (c.334C>T + c.937G>T) and C172G + D313Y (c.514T>G + c.937G>T). The D313Y lesion was previously identified in classically affected males as the single mutation [Eng et al., 1993] or in cis with another missense mutation, D313Y + G411D (c.937G>T + c.1232G>A) [Guffon et al., 1998]. To determine whether the D313Y mutation was a deleterious mutation or a coding region sequence variant, the frequency of D313Y in normal X‐chromosomes, as well as its enzymatic activity and subcellular localization in COS‐7 cells was determined. D313Y occurred in 0.45% of 883 normal X‐chromosomes, while the R112C, C172G, and G411D missense mutations were not detected in over 500 normal X‐chromosomes. Expression of D313Y in COS‐7 cells resulted in& tilde;60% of wild‐type enzymatic activity and showed lysosomal localization, while R112C, C172G, G411D, and the double‐mutated constructs had markedly reduced or no detectable activity and were all retained in the endoplasmic reticulum. The expressed D313Y enzyme was stable at lysosomal pH (pH 4.6), while at neutral pH (pH 7.4), it had decreased activity. A molecular homology model of human α‐Gal A, based on the X‐ray crystal structure of chicken α‐galactosidase B (α‐Gal B; α‐N‐acetylgalactosaminidase) was generated [Garman et al., 2002], which provided evidence that D313Y did not markedly disrupt the α‐Gal A enzyme structure. Thus, D313Y is a rare exonic variant with about 60% of wild‐type activity in vitro and reduced activity at neutral pH, resulting in low plasma α‐Gal A activity. Hum Mutat 22:486–492, 2003. © 2003 Wiley‐Liss, Inc.
Author Desnick, Robert J.
Yasuda, Makiko
Maire, Irene
Burnett, Roger M.
Benson, Stacy D.
Shabbeer, Junaid
Author_xml – sequence: 1
  givenname: Makiko
  surname: Yasuda
  fullname: Yasuda, Makiko
  organization: Department of Human Genetics, Mount Sinai School of Medicine, New York, New York
– sequence: 2
  givenname: Junaid
  surname: Shabbeer
  fullname: Shabbeer, Junaid
  organization: Department of Human Genetics, Mount Sinai School of Medicine, New York, New York
– sequence: 3
  givenname: Stacy D.
  surname: Benson
  fullname: Benson, Stacy D.
  organization: The Wistar Institute, Philadelphia, Pennsylvania
– sequence: 4
  givenname: Irene
  surname: Maire
  fullname: Maire, Irene
  organization: Laboratoire de Biochimie Pediatrique, Hopital Debrousse, Lyon, France
– sequence: 5
  givenname: Roger M.
  surname: Burnett
  fullname: Burnett, Roger M.
  organization: The Wistar Institute, Philadelphia, Pennsylvania
– sequence: 6
  givenname: Robert J.
  surname: Desnick
  fullname: Desnick, Robert J.
  email: 10029rjdesnick@mssm.edu
  organization: Department of Human Genetics, Mount Sinai School of Medicine, New York, New York
BackLink https://www.ncbi.nlm.nih.gov/pubmed/14635108$$D View this record in MEDLINE/PubMed
BookMark eNpFkU1u2zAQhYkgRf7aTQ5QcNWdGlIUTTG7wGnionGSRYyiK2IkDmM2lOSKEhL5Vr1IzxTZTtvVPLz53izmHZP9uqmRkFPOPnPG0rNlX_WjSpXcI0ec6TwZ7Wx_o6VOlNLZITmO8SdjLJdSHJBDnk2E5Cw_IusrKNqBWh8RIp7T6RJaKDts_Ro639S0cfTP7-QRwug20duRohfUNn0RkFZ9t6UihdrSbon0UnDxg64CxAoo1uuhQrqK2NvGovOlx7ocKISAAd-Tdw5CxA9v84Qsrr48TGfJzd311-nFTeJTrmWinGYZz20BEoRKUTApU50qzizKUqPLRjfXUpVOA5OZk1ZrrZwrFExknosT8ml3d9U2v3qMnal8LDEEqLHpo1FcaKHlBvz4BvZFhdasWl9BO5i_3xoBvgOefcDh_56ZTQ9m04PZ9mBmi_liq8ZMssv42OHLvwy0T2aixIh-v7023y7ns9u5vjcP4hVs6I1f
ContentType Journal Article
Copyright Copyright © 2003 Wiley‐Liss, Inc.
Copyright 2003 Wiley-Liss, Inc.
Copyright_xml – notice: Copyright © 2003 Wiley‐Liss, Inc.
– notice: Copyright 2003 Wiley-Liss, Inc.
DBID BSCLL
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1002/humu.10275
DatabaseName Istex
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1098-1004
EndPage 492
ExternalDocumentID 14635108
HUMU10275
ark_67375_WNG_KDMHNM9P_T
Genre article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S
Journal Article
GrantInformation_xml – fundername: Genzyme Corporation
– fundername: National Center of Research Resources, National Institutes of Health
  funderid: 5 MO1 RR00071
– fundername: National Institutes of Health
  funderid: R37 DK34045, 5 P30 HD28822
– fundername: NCRR NIH HHS
  grantid: 5M01RR00071
– fundername: NICHD NIH HHS
  grantid: 5 P30 HD28822
– fundername: NIDDK NIH HHS
  grantid: R37 DK34045
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
29I
31~
33P
3SF
3V.
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5VS
66C
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
88A
88E
8C1
8FE
8FH
8FI
8FJ
8R4
8R5
8UM
930
A03
AAESR
AAEVG
AAHHS
AAJEY
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABHUG
ABIJN
ABJNI
ABPVW
ABUWG
ABWRO
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFS
ACPOU
ACPRK
ACSCC
ACXBN
ACXME
ACXQS
ADAWD
ADBBV
ADDAD
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIMD
AENEX
AEQDE
AEQTP
AEUQT
AFBPY
AFGKR
AFKRA
AFPWT
AFVGU
AFZJQ
AGJLS
AHMBA
AIURR
AIWBW
AJAOE
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AMBMR
AMYDB
ASPBG
ATUGU
AUFTA
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BBNVY
BDRZF
BENPR
BFHJK
BHBCM
BHPHI
BMNLL
BMXJE
BNHUX
BPHCQ
BROTX
BRXPI
BSCLL
BVXVI
BY8
C45
CCPQU
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
DU5
DVXWH
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FYUFA
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HCIFZ
HF~
HHY
HHZ
HMCUK
HVGLF
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LK8
LOXES
LP6
LP7
LUTES
LW6
LYRES
M0L
M1P
M66
M7P
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OVD
P2P
P2W
P2X
P4D
PALCI
PIMPY
PQQKQ
PROAC
PSQYO
Q.N
Q11
Q2X
QB0
QRW
R.K
RHX
RIWAO
RJQFR
ROL
RWI
RWV
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
UDS
UKHRP
V2E
W8V
W99
WBKPD
WIB
WIH
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WTM
WXSBR
WYISQ
X7M
XG1
XSW
XV2
ZZTAW
~IA
~KM
~WT
24P
ALIPV
ALUQN
H13
OIG
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-i2195-7f90418dba5a372e3055292710de5c9ef43728957cf9a054f5d9997ffb7a65883
IEDL.DBID DR2
ISSN 1059-7794
IngestDate Fri Aug 16 07:50:09 EDT 2024
Sat Sep 28 07:42:13 EDT 2024
Sat Aug 24 00:48:12 EDT 2024
Wed Jan 17 05:00:49 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
License Copyright 2003 Wiley-Liss, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-i2195-7f90418dba5a372e3055292710de5c9ef43728957cf9a054f5d9997ffb7a65883
Notes Communicated by William Sly
ArticleID:HUMU10275
National Institutes of Health - No. R37 DK34045, 5 P30 HD28822
istex:BBE1A4FE11823A315BBC6E55DE8546A78F6B8866
National Center of Research Resources, National Institutes of Health - No. 5 MO1 RR00071
ark:/67375/WNG-KDMHNM9P-T
Genzyme Corporation
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 14635108
PQID 71393958
PQPubID 23479
PageCount 7
ParticipantIDs proquest_miscellaneous_71393958
pubmed_primary_14635108
wiley_primary_10_1002_humu_10275_HUMU10275
istex_primary_ark_67375_WNG_KDMHNM9P_T
PublicationCentury 2000
PublicationDate 2003-12
December 2003
2003-Dec
20031201
PublicationDateYYYYMMDD 2003-12-01
PublicationDate_xml – month: 12
  year: 2003
  text: 2003-12
PublicationDecade 2000
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: United States
PublicationTitle Human mutation
PublicationTitleAlternate Hum. Mutat
PublicationYear 2003
Publisher Wiley Subscription Services, Inc., A Wiley Company
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
References Germain DP, Shabbeer J, Cotigny S, Desnick RJ. 2002. Fabry disease: twenty novel α-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes. Mol Med 8:306-312.
Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, Jiang J-S, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice LM, Simonson T, Warren GL. 1998. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D54:905-921.
Eng CM, Ashley GA, Burgert TS, Enriquez AL, D'Souza M, Desnick RJ. 1997. Fabry disease: thirty-five mutations in the α-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 3:174-182.
Higgins M, Davies JP, Chen FW, Ioannou YA. 1999. Niemann-Pick C1 is a late endosome-resident protein that transiently associates with lysosomes and the trans-golgi network. Mol Genet Metab 68:1-13.
Ishida S, Ichimura K, Yamakage A, Matsuzaki S, Yamazaki S. 1997. Missense mutation in exon 2 of α-galactosidase A in patient with Fabry disease. Arch Dermatol Res 289:303-305.
Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTAL-X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25:4876-4882.
Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. 1993. Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease. Am J Hum Genet 53:1186-1197.
Guffon N, Froissart R, Chevalier-Porst F, Maire I. 1998. Mutation analysis in 11 French patients with Fabry disease. Hum Mutat Suppl 1:S288-S290.
Jones TA, Zou J-Y, Cowan SW, Kjeldgaard M. 1991. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A47:110-119.
Garman SC, Hannick L, Zhu A, Garboczi DN. 2002. The 1.9-Å structure of α-N-acetylgalactosaminidase: molecular basis of glycosidase deficiency diseases. Structure 10:425-434.
Kornreich R, Desnick RJ, Bishop DF. 1989. Nucleotide sequence of the human α-galactosidase A gene. Nucleic Acids Res 17:3301-3302.
Ishii S, Sakuraba H, Suzuki Y. 1992. Point mutations in the upstream region of the α-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum Genet 89:29-32.
Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A, Kanzaki T, Enriquez AL, Eng CM, Tanaka H, Tei C, Desnick RJ. 2003. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 64:801-807.
Shabbeer J, Yasuda M, Luca E, Desnick RJ. 2002. Fabry disease: 45 novel mutations in the α-galactosidase A gene causing the classical phenotype. Mol Genet Metab 76:23-30.
Garman SC, Garboczi DN. 2002. Structural basis of Fabry disease. Mol Genet Metab 77:3-11.
Ioannou YA, Zeidner KM, Grace ME, Desnick RJ. 1998. Human α-galactosidase A: glycosylation site 3 is essential for enzyme solubility. Biochem J 332:789-797.
Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W. 1973. Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. α-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 81:157-171.
von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, Christomanou H, Kandolf R, Bishop DF, Desnick RJ. 1991. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 324:395-399.
Bishop DF, Calhoun DH, Bernstein HS, Hantzopoulos P, Quinn M, Desnick RJ. 1986. Human α-galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme. Proc Natl Acad Sci USA 83:4859-4863.
Wang AM, Desnick RJ. 1991. Structural organization and complete sequence of human α-N-acetylgalactosaminidase gene: homology with the α-galactosidase A gene provides evidence of evolution from a common ancestral gene. Genomics 10:133-142.
1997; 289
1973; 81
1986; 83
2001
1998; D54
1991; 10
1997; 25
1993; 53
2002; 10
2002; 76
2002; 77
2002; 8
1999; 68
1991; A47
1998; 1
1997; 3
1998; 332
1992; 89
1991; 324
2003; 64
1989; 17
References_xml – volume: 53
  start-page: 1186
  year: 1993
  end-page: 1197
  article-title: Nature and frequency of mutations in the α‐galactosidase A gene that cause Fabry disease
  publication-title: Am J Hum Genet
– volume: 289
  start-page: 303
  year: 1997
  end-page: 305
  article-title: Missense mutation in exon 2 of α‐galactosidase A in patient with Fabry disease
  publication-title: Arch Dermatol Res
– start-page: 3733
  year: 2001
  end-page: 3774
– volume: A47
  start-page: 110
  year: 1991
  end-page: 119
  article-title: Improved methods for building protein models in electron density maps and the location of errors in these models
  publication-title: Acta Crystallogr
– volume: 10
  start-page: 425
  year: 2002
  end-page: 434
  article-title: The 1.9‐Å structure of α‐N‐acetylgalactosaminidase: molecular basis of glycosidase deficiency diseases
  publication-title: Structure
– volume: 8
  start-page: 306
  year: 2002
  end-page: 312
  article-title: Fabry disease: twenty novel α‐galactosidase A mutations and genotype‐phenotype correlations in classical and variant phenotypes
  publication-title: Mol Med
– volume: 89
  start-page: 29
  year: 1992
  end-page: 32
  article-title: Point mutations in the upstream region of the α‐galactosidase A gene exon 6 in an atypical variant of Fabry disease
  publication-title: Hum Genet
– volume: 332
  start-page: 789
  year: 1998
  end-page: 797
  article-title: Human α‐galactosidase A: glycosylation site 3 is essential for enzyme solubility
  publication-title: Biochem J
– volume: D54
  start-page: 905
  year: 1998
  end-page: 921
  article-title: Crystallography and NMR system: a new software suite for macromolecular structure determination
  publication-title: Acta Crystallogr
– volume: 76
  start-page: 23
  year: 2002
  end-page: 30
  article-title: Fabry disease: 45 novel mutations in the α‐galactosidase A gene causing the classical phenotype
  publication-title: Mol Genet Metab
– volume: 83
  start-page: 4859
  year: 1986
  end-page: 4863
  article-title: Human α‐galactosidase A: nucleotide sequence of a cDNA clone encoding the mature enzyme
  publication-title: Proc Natl Acad Sci USA
– volume: 25
  start-page: 4876
  year: 1997
  end-page: 4882
  article-title: The CLUSTAL‐X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools
  publication-title: Nucleic Acids Res
– volume: 17
  start-page: 3301
  year: 1989
  end-page: 3302
  article-title: Nucleotide sequence of the human α‐galactosidase A gene
  publication-title: Nucleic Acids Res
– volume: 64
  start-page: 801
  year: 2003
  end-page: 807
  article-title: Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype
  publication-title: Kidney Int
– volume: 10
  start-page: 133
  year: 1991
  end-page: 142
  article-title: Structural organization and complete sequence of human α‐ ‐acetylgalactosaminidase gene: homology with the α‐galactosidase A gene provides evidence of evolution from a common ancestral gene
  publication-title: Genomics
– volume: 324
  start-page: 395
  year: 1991
  end-page: 399
  article-title: An atypical variant of Fabry's disease with manifestations confined to the myocardium
  publication-title: N Engl J Med
– volume: 68
  start-page: 1
  year: 1999
  end-page: 13
  article-title: Niemann‐Pick C1 is a late endosome‐resident protein that transiently associates with lysosomes and the trans‐golgi network
  publication-title: Mol Genet Metab
– volume: 77
  start-page: 3
  year: 2002
  end-page: 11
  article-title: Structural basis of Fabry disease
  publication-title: Mol Genet Metab
– volume: 81
  start-page: 157
  year: 1973
  end-page: 171
  article-title: Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes. α‐galactosidase activities in plasma, serum, urine, and leukocytes
  publication-title: J Lab Clin Med
– volume: 1
  start-page: S288
  year: 1998
  end-page: S290
  article-title: Mutation analysis in 11 French patients with Fabry disease
  publication-title: Hum Mutat Suppl
– volume: 3
  start-page: 174
  year: 1997
  end-page: 182
  article-title: Fabry disease: thirty‐five mutations in the α‐galactosidase A gene in patients with classic and variant phenotypes
  publication-title: Mol Med
SSID ssj0008553
Score 2.1722937
Snippet Fabry disease, an X‐linked inborn error of glycosphingolipid catabolism, results from mutations in the gene encoding the lysosomal exoglycohydrolase,...
Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from mutations in the gene encoding the lysosomal exoglycohydrolase,...
SourceID proquest
pubmed
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 486
SubjectTerms Alleles
alpha-Galactosidase - chemistry
alpha-Galactosidase - genetics
alpha-Galactosidase - metabolism
Amino Acid Substitution
Animals
Catalytic Domain
Cercopithecus aethiops
Chickens
COS Cells
DNA - chemistry
DNA - genetics
DNA Mutational Analysis
Endoplasmic Reticulum - enzymology
Enzyme Stability
Fabry disease
Fabry Disease - blood
Fabry Disease - enzymology
Fabry Disease - genetics
GLA
Humans
Hydrogen-Ion Concentration
lysosomal storage disease
Lysosomes - enzymology
Male
Models, Molecular
Mutation
mutation analysis
Plasmids - genetics
Protein Structure, Secondary
Protein Structure, Tertiary
pseudodeficiency
Recombinant Proteins - isolation & purification
Recombinant Proteins - metabolism
structural homology model
Transfection
Title Fabry disease: Characterization of α-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele
URI https://api.istex.fr/ark:/67375/WNG-KDMHNM9P-T/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fhumu.10275
https://www.ncbi.nlm.nih.gov/pubmed/14635108
https://search.proquest.com/docview/71393958
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxEB6VIhAXHuUVHsEHxAFp22Q3rm3EpaQNEWijqmpEOCDL3rUFarMbJVmJVBz4CfwV_gg_gl_CzDoPgbjAZbWSvc8Zez57Zr4BeGpiJ9o-ziLnnIqIUC4ySubRfkbbOMpa6Wm_Ix3s94edNyM-2oKXq1yYwA-x3nCjkVHP1zTAjZ3tbUhDP1bjiogHBGWYE5MeIaKTDXeU5DxE1-PjBWrdmps03ttcipCU_ubnv-HL3-FqbW96N-DD6k1DmMnZbjW3u9nFHySO__spN-H6Eoiyg6A5t2DLFTtwJZSmXOzA1XTpdL8NX3rGThds6cp5wbprjueQwslKz358__n1Gxobqt6D-o392AHLy8qeOzaugrt_xkyRMwSc7DBpJ-_ZBIH72DBXXCzGjk1mrsrL3BGjBaWDMirycu7uwLB3dNrtR8uiDdGnmOo-Cq9anbbMreEmEbEjRrFYxQhkcscz5Tw5CqXiIvPKIF70PEeMKry3wiAaksld2C7Kwt0HhrhfdUwnd5IbYiYzgqMxtYgyRGySVqsBz2rh6Ukg5tBmekZxaoLrd4PX-u1h2h-k6lifNuDJSroaRw-5REzhymqmcYmOGsllA-4Foa_vhRYkwfkKW57Xots01DzPsSah6Vpouj9Mh_XZg3_p_BCuhchAio15BNvzaeUeI8KZ2yZcEiOBR9ltN-Hyq6PB8Umz1u5fDR77Xw
link.rule.ids 315,786,790,1382,27955,27956,31753,33300,33778,46327,46751
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELagCOiFnwLt8lcfEAektLvOuo57q7osgTYrhHZFe7LsxBZVu8lqdyOxFQcegVfpi_AQPAkzdtgViAvcItmJEs-M58vM-BtCXmhmRcexPLLWyggJ5SItkyLayzGMI41JHMY7ssFeOuq-O-EnTW0OnoUJ_BDLgBtaht-v0cAxIL27Yg39VI9rZB4Q_Dq5AfbO0S57H1bsUQnnob4eXkCA3i3ZSdnu6l4Apbien_-GMH8HrN7j9O-GtqozT1SIhSbnO_Xc7OSXf9A4_vfH3CN3GixKD4Ly3CfXbLlBbobulIsNcitr8u4PyJe-NtMFbbI5-_RwSfMcTnHSytHvVz--fgN_gw18QMVhHj2gRVWbC0vHdcj4z6guCwqYk_biTnxKJ4Ddx5ra8nIxtnQys3VRFRZJLfBEKMU-Lxf2IRn1Xw8P06jp2xCdMWz9KJxsdztJYTTXsWAWScWYZIBlCstzaR3mChPJRe6kBsjoeAEwVThnhAZAlMSPyFpZlXaLUID-squ7hU24RnIyLTj4UwNAQzAdt9st8tJLT00CN4fS03MsVRNcfRy8UUe9LB1k8r0atsj2L_EqMCDMiujSVvVMwV86KCVPWmQzSH35LHAiMWxZMPLKy2414KmemUKhKS80lY6ykb96_C-Tt8ntdJgdq-O3g6MnZD0UCmKpzFOyNp_W9hkAnrl57tX6JxHM_DE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LbxMxEB6VIiouPMorvOoD4oC0beJdx2vEpWoIgZKoQo1oD8jyrm2B2uxGSVYiFQd-An-FP8KP4Jcws85DIC5wW8neh3fGns8z428AnhjuZMvzPHLOqYgI5SKjUhu1c3LjqCxLPfk7-oN2b5i8OREnG_BieRYm8EOsHG40M-r1mib42Pq9NWnox2pUEfGAFJfgctKOOW29Ou_W5FGpECG9Ht8vUe1W5KR8b30vYlL6nZ__BjB_x6u1welehw_LTw15Jme71SzbzS_-YHH837HcgGsLJMr2g-rchA1XbMOVUJtyvg1b_UXU_RZ86ZpsMmeLWM5zdrAieQ5nOFnp2Y_vP79-Q2tD5XtQwbEf22e2rLJzx0ZViPdPmSksQ8TJOnErPmVjRO4jw1xxMR85Np66ypbWEaUFnQdlVOXl3N2GYffl8UEvWlRtiD5xKvwovWomrdRmRphYckeUYlxxRDLWiVw5T5HCVAmZe2UQMHphEaRK7zNpEA6l8R3YLMrC3QOGwF8lJrEuFYaoyYwUaE0zhBmSm7jZbMDTWnh6HJg5tJmcUaKaFPr94JU-7PR7g7460scN2FlKV-P0oZiIKVxZTTXu0VElRdqAu0Hoq2ehCYlxwcKWZ7Xo1g010TPXJDRdC033hv1hfXX_XzrvwNZRp6vfvh4cPoCrIUuQ8mQewuZsUrlHiHZm2eNaqX8BKOr64A
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fabry+disease%3A+characterization+of+alpha-galactosidase+A+double+mutations+and+the+D313Y+plasma+enzyme+pseudodeficiency+allele&rft.jtitle=Human+mutation&rft.au=Yasuda%2C+Makiko&rft.au=Shabbeer%2C+Junaid&rft.au=Benson%2C+Stacy+D&rft.au=Maire%2C+Irene&rft.date=2003-12-01&rft.eissn=1098-1004&rft.volume=22&rft.issue=6&rft.spage=486&rft_id=info:doi/10.1002%2Fhumu.10275&rft_id=info%3Apmid%2F14635108&rft.externalDocID=14635108
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1059-7794&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1059-7794&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1059-7794&client=summon